weight loss Archives - Well Referenced

The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials

This 2020 systematic review and meta-analysis evaluated the effects of berberine supplementation on obesity-related parameters, inflammation, and liver function enzymes. Analyzing 12 randomized controlled trials, the study found that berberine intake led to significant reductions in body weight (mean difference: -2.07 kg), body mass index (BMI), waist circumference, and C-reactive

June 26, 2025 No Comments

Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial

This 2017 randomized, double-blind, placebo-controlled crossover trial evaluated the effects of α-lipoic acid (ALA) supplementation on body weight in overweight or obese individuals. A total of 103 Chinese Han participants with a BMI ≥25 kg/m² were randomized to receive either 1200 mg/day of ALA or placebo for 8 weeks, followed

June 26, 2025 No Comments

Improved Function With Enhanced Protein Intake per Meal: A Pilot Study of Weight Reduction in Frail, Obese Older Adults

This 2016 randomized controlled trial assessed the impact of meal-based protein enhancement on weight loss and physical function in 67 obese adults aged ≥60 with functional limitations. Participants were assigned to either a traditional weight loss diet or one with >30g protein per meal. Both groups experienced significant weight loss

June 26, 2025 No Comments

Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet

This 2004 randomized controlled trial evaluated the effects of a high-soy-protein, low-fat diet on body composition in overweight and obese individuals. Ninety participants with a BMI between 27.5 and 35 were assigned to one of three groups: lifestyle education only (LE-G), soy-based diet without exercise (SD-G), or soy-based diet with

June 26, 2025 No Comments

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide

June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

June 26, 2025 No Comments

Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans

This 2014 randomized controlled trial assessed the effects of Hibiscus sabdariffa extract (HSE) on obesity and liver steatosis in overweight individuals (BMI ≥27). Over 12 weeks, participants consuming HSE exhibited significant reductions in body weight, BMI, body fat, waist-to-hip ratio, and serum free fatty acids compared to controls. Imaging studies

June 26, 2025 No Comments

Efficacy and Safety of Beloranib for Weight Loss in Obese Adults: A Randomized Controlled Trial

This 2015 phase II, double-blind, randomized controlled trial assessed the efficacy and safety of beloranib, a methionine aminopeptidase 2 (MetAP2) inhibitor, in 147 obese adults over 12 weeks. Participants received subcutaneous beloranib at doses of 0.6, 1.2, or 2.4 mg, or placebo, without dietary or exercise interventions. Beloranib induced dose-dependent

June 26, 2025 No Comments

Phentermine/Topiramate Extended-Release Capsules (Qsymia) for Weight Loss

This 2013 review evaluates the efficacy and safety of phentermine/topiramate extended-release (PHEN/TPM ER) capsules, marketed as Qsymia, for obesity management. Clinical trials demonstrated significant weight loss ranging from 8.1% to 10.9% with mid to high doses, compared to 1.4% to 1.8% with placebo. PHEN/TPM ER also led to reductions in

June 26, 2025 No Comments

New Drug Therapies for the Treatment of Overweight and Obese Patients

This 2013 review discusses pharmacologic options for obesity management, emphasizing the role of medications as adjuncts to lifestyle modifications. At the time, four FDA-approved drugs were available: orlistat, lorcaserin (Belviq), phentermine/topiramate (Qsymia), and naltrexone/bupropion (Contrave). Orlistat functions by inhibiting fat absorption, while the others act centrally to suppress appetite. Clinical

June 26, 2025 No Comments

Tag: weight loss